Last reviewed · How we verify
LAU-7b for 3 cycles
At a glance
| Generic name | LAU-7b for 3 cycles |
|---|---|
| Also known as | fenretinide |
| Sponsor | Laurent Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of LAU-7b for the Treatment of Long COVID in Adults (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAU-7b for 3 cycles CI brief — competitive landscape report
- LAU-7b for 3 cycles updates RSS · CI watch RSS
- Laurent Pharmaceuticals Inc. portfolio CI